All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On September 24, 2024, the U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application for roflumilast foam 0.3% to treat scalp and body psoriasis in individuals aged ≥12 years.1 This decision is based on the positive results from the ARRECTOR (NCT05028582) trial.
Roflumilast cream 0.3% is already approved in patients aged ≥6 years with plaque psoriasis.
ARRECTOR is an ongoing, double-blind, vehicle-controlled phase III trial investigating the safety and efficacy of roflumilast foam 0.3% in patients with scalp and body psoriasis. The primary endpoints are achieving Scalp-Investigator Global Assessment (S-IGA) and Body-Investigator Global Assessment (B-IGA).
Overall, 432 patients aged ≥12 years with body and scalp plaque psoriasis were included.
At Week 8:
The most commonly reported adverse reactions in ≥1% of patients were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox